Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) have received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus price objective of $12.00 for the company and are anticipating that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Brainstorm Cell Therapeutics an industry rank of 102 out of 265 based on the ratings given to related companies.

Separately, Maxim Group set a $9.00 price target on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 16th.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. KCG Holdings Inc. boosted its position in shares of Brainstorm Cell Therapeutics by 4.6% during the 1st quarter. KCG Holdings Inc. now owns 41,537 shares of the biotechnology company’s stock worth $177,000 after acquiring an additional 1,820 shares in the last quarter. Vanguard Group Inc. boosted its position in Brainstorm Cell Therapeutics by 2.8% in the second quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock valued at $2,733,000 after buying an additional 17,657 shares in the last quarter. Finally, Sphera Funds Management LTD. acquired a new stake in Brainstorm Cell Therapeutics in the second quarter valued at approximately $2,759,000. Institutional investors and hedge funds own 12.89% of the company’s stock.

Shares of Brainstorm Cell Therapeutics (NASDAQ BCLI) traded down $0.09 on Friday, hitting $3.98. 49,878 shares of the stock traded hands, compared to its average volume of 134,298. Brainstorm Cell Therapeutics has a 12 month low of $2.07 and a 12 month high of $5.18.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its earnings results on Tuesday, October 17th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.03. During the same quarter in the prior year, the firm earned ($0.09) EPS. research analysts predict that Brainstorm Cell Therapeutics will post -0.37 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/01/zacks-brainstorm-cell-therapeutics-inc-bcli-given-12-00-average-target-price-by-analysts.html.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get a free copy of the Zacks research report on Brainstorm Cell Therapeutics (BCLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.